- Home
- ETN vs GILD Comparison
ETN vs GILD Comparison
Compare ETN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETN
- GILD
- Stock Information
- Founded
- ETN 1916
- GILD 1987
- Country
- ETN Ireland
- GILD United States
- Employees
- ETN N/A
- GILD N/A
- Industry
- ETN Industrial Machinery/Components
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETN Technology
- GILD Health Care
- Exchange
- ETN Nasdaq
- GILD Nasdaq
- Market Cap
- ETN 127.9B
- GILD 138.7B
- IPO Year
- ETN N/A
- GILD 1992
- Fundamental
- Price
- ETN $392.23
- GILD $116.20
- Analyst Decision
- ETN Buy
- GILD Buy
- Analyst Count
- ETN 20
- GILD 24
- Target Price
- ETN $374.11
- GILD $111.91
- AVG Volume (30 Days)
- ETN 2.1M
- GILD 6.1M
- Earning Date
- ETN 08-05-2025
- GILD 08-07-2025
- Dividend Yield
- ETN 1.06%
- GILD 2.72%
- EPS Growth
- ETN 17.05
- GILD 1118.07
- EPS
- ETN 9.91
- GILD 4.73
- Revenue
- ETN $25,312,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- ETN $10.66
- GILD $1.69
- Revenue Next Year
- ETN $7.74
- GILD $3.67
- P/E Ratio
- ETN $39.56
- GILD $24.56
- Revenue Growth
- ETN 7.00
- GILD 4.68
- 52 Week Low
- ETN $231.85
- GILD $72.43
- 52 Week High
- ETN $392.92
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- ETN 76.87
- GILD 63.27
- Support Level
- ETN $365.00
- GILD $107.75
- Resistance Level
- ETN $384.51
- GILD $113.89
- Average True Range (ATR)
- ETN 7.24
- GILD 2.54
- MACD
- ETN 1.41
- GILD 0.38
- Stochastic Oscillator
- ETN 98.23
- GILD 85.79
About ETN Eaton Corporation PLC
Founded in 1911 by Joseph Eaton, the eponymous company began by selling truck axles in New Jersey. Eaton has since become an industrial powerhouse largely through acquisitions in various end markets. Eaton's portfolio can broadly be divided into two parts: its electrical and industrial businesses. Its electrical portfolio (representing around 70% of company revenue) sells components within data centers, utilities, and commercial and residential buildings, while its industrial business (30% of revenue) sells components within commercial and passenger vehicles and aircraft. Eaton receives favorable tax treatment as a domiciliary of Ireland, but it generates over half of its revenue within the US.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).